Medical device company working to revolutionize patient care and outcomes
COLUMBIA, Md., (October 31, 2024) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $250,000 Seed Funds investment in NeuroIntact. TEDCO’s Seed Funds aim to reach prospective businesses showing potential of being venture fundable or other forms of corporate venture, such as follow-on funding.
“Elevated pressure in the brain as a result of a cerebral edema can be not only damaging, but also life-threatening without proper treatment,” said Bryan Nicholson, president of NeuroIntact. “That’s why we’re working on creating a solution and thanks to this recent investment from TEDCO, we can continue progressing in our research and development efforts.”
NeuroIntact, located in Baltimore, Md., is a medical device company dedicated to revolutionizing patient care and outcomes by preserving neurological function. The company explains that, through their targeted temperature management (TTM), providers can manage elevated intracranial pressure or edemas with fewer side effects compared to whole-body cooling.
“NeuroIntact recognized a gap in the current process of patient care and is working to find a viable solution,” said Teddy Gresser, director of TEDCO’s Seed Funds. “This innovative thinking has the potential to lessen risk while supporting providers and patients across the world. With this perspective, the company is a great example of the kinds of innovations TEDCO seeks to invest in through our Seed Funds.”
Seed Funds through TEDCO are essential for businesses with the potential to grow their sustainability through customer revenue or other corporate ventures. For more information regarding TEDCO Seed Funds, please visit https://www.tedcomd.com/funding/seed-funds.